The Market Reports

Synopsis
The global market for Drug Repositioning was estimated to be worth US$ 28780 million in 2024 and is forecast to a readjusted size of US$ 40830 million by 2031 with a CAGR of 4.7% during the forecast period 2025-2031.
Drug repurposing (also called drug repositioning, reprofiling or re-tasking) is a strategy for identifying new uses for approved or investigational drugs that are outside the scope of the original medical indication. This strategy offers various advantages over developing an entirely new drug for a given indication.
The drug repositioning market is driven by the growing demand for cost-effective and time-saving drug development strategies. Traditional drug discovery can take over a decade and cost billions of dollars, with a high risk of failure during clinical trials. Repositioning, on the other hand, allows pharmaceutical companies to repurpose known drugs with existing safety and pharmacokinetic profiles, thereby accelerating time to market and reducing development risk. This approach is especially appealing for rare diseases, cancer, and neurodegenerative disorders where treatment options are limited. Additionally, advances in data mining, artificial intelligence, and systems biology have improved the ability to identify new drug-disease relationships, fueling further interest. Regulatory agencies such as the FDA and EMA also support repositioning by offering faster review pathways and incentives for orphan indications, making this strategy increasingly viable from a business perspective.
Despite its advantages, the drug repositioning market faces several challenges. One of the major issues is intellectual property protection—many repositioned drugs are off-patent, making it difficult for companies to secure exclusivity and justify investment. In cases where patent life can be extended through new formulations or uses, legal and regulatory hurdles still exist. Another challenge lies in clinical validation; while safety data may already be available, proving efficacy for a new indication still requires substantial clinical trial investment. Moreover, the lack of centralized, standardized databases for repositioning candidates limits discovery efficiency. The fragmented nature of available data—spread across academic publications, clinical trial registries, and real-world evidence—makes it hard to integrate and analyze comprehensively. Finally, collaboration between industry and academia, which is crucial for repositioning, is often hindered by misaligned goals and timelines.
This report aims to provide a comprehensive presentation of the global market for Drug Repositioning, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Drug Repositioning by region & country, by Type, and by Application.
The Drug Repositioning market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drug Repositioning.
Market Segmentation
By Company
Teva
Novartis
Mylan
Johnson & Johnson
Pfizer
Bausch Health
GSK
ChemRar Group
Glenmark
Fujifilm
Dr. Reddy
R-Pharma
Segment by Type
Generic Drugs
Clinical Trial Failed Drugs
Segment by Application
Cardiovascular Diseases
Mental Illness
Cancer
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Drug Repositioning company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Drug Repositioning in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Drug Repositioning in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Index